ISN-KDIGO Webinar: Novel Anemia Therapies
- 5:00 PM CEST
HIF-PH inhibitors are a new class of oral drugs for the treatment of anaemia in CKD patients. They demonstrated comparable efficacy to ESA in anemia correction and maintenance. Despite expectations, they have not shown better outcomes compared to ESA. This presentation will start from a clinical case, and propose some point of reflections on which patients could be candidate for the use of this new class of drugs
- Understand the mechanism of action and pharmacological properties of HIF-PH inhibitors as a new class of oral drugs for the treatment of anemia in chronic kidney disease (CKD) patients.
- Analyze the comparative efficacy of HIF-PH inhibitors and erythropoiesis-stimulating agents (ESA) in correcting and maintaining anemia in CKD patients.
- Evaluate the current evidence regarding the clinical outcomes associated with HIF-PH inhibitors compared to ESA and identify the factors that may influence patient selection for the use of HIF-PH inhibitors as a potential treatment option for anemia in CKD.
- Ku E, Del Vecchio L, Eckardt KU, et al.; for Conference Participants. Novel Anemia Therapies in Chronic Kidney Disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023 May 24. Epub ahead of print. PMID: 37236424.
David Wheeler (UK)
Volker Haase (USA)
Lucia Del Vecchio (Italy)